![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Saphris, Sycrest, Secuado, others |
Other names | Asenapine maleate, ORG-5222 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a610015 |
License data | |
Pregnancy category |
|
Routes of administration | Under the tongue |
Drug class | Atypical antipsychotic |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 35% (sublingual), <2% (by mouth) [3] [4] [1] [5] |
Protein binding | 95% [3] [4] [1] [5] |
Metabolism | hepatic (glucurinodation by UGT1A4 and oxidative metabolism by CYP1A2) [3] [4] [1] [5] |
Elimination half-life | 24 hours [3] [4] [1] [5] |
Excretion | Kidney (50%), Faecal (40%; ~5–16% as unchanged drug in faeces) [3] [4] [1] [5] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C17H16ClNO |
Molar mass | 285.77 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Asenapine, sold under the brand name Saphris among others, is an atypical antipsychotic used to treat schizophrenia and mania in bipolar disorder. [6] [2] Use in older people with dementia related psychosis may increase the risk of death. [6] It is used under the tongue. [7]
Common side effects include sleepiness, dizziness, weight gain, movement disorders, and numbness within the mouth. [6] Other side effects may include stroke, neuroleptic malignant syndrome, tardive dyskinesia, diabetes, low white blood cells, seizures, and QT prolongation. [6] How it works is not clear, but is believed to involve blocking serotonin and dopamine receptors. [2]
Asenapine was approved for medical use in the United States in 2009 and Europe in 2010. [6] [2] The first generic versions were approved in 2020. [8] In the United Kingdom it costs the NHS about £100 per month as of 2021. [9] This amount in the United States is about 200 USD. [10]
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Saphris, Sycrest, Secuado, others |
Other names | Asenapine maleate, ORG-5222 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a610015 |
License data | |
Pregnancy category |
|
Routes of administration | Under the tongue |
Drug class | Atypical antipsychotic |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 35% (sublingual), <2% (by mouth) [3] [4] [1] [5] |
Protein binding | 95% [3] [4] [1] [5] |
Metabolism | hepatic (glucurinodation by UGT1A4 and oxidative metabolism by CYP1A2) [3] [4] [1] [5] |
Elimination half-life | 24 hours [3] [4] [1] [5] |
Excretion | Kidney (50%), Faecal (40%; ~5–16% as unchanged drug in faeces) [3] [4] [1] [5] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C17H16ClNO |
Molar mass | 285.77 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Asenapine, sold under the brand name Saphris among others, is an atypical antipsychotic used to treat schizophrenia and mania in bipolar disorder. [6] [2] Use in older people with dementia related psychosis may increase the risk of death. [6] It is used under the tongue. [7]
Common side effects include sleepiness, dizziness, weight gain, movement disorders, and numbness within the mouth. [6] Other side effects may include stroke, neuroleptic malignant syndrome, tardive dyskinesia, diabetes, low white blood cells, seizures, and QT prolongation. [6] How it works is not clear, but is believed to involve blocking serotonin and dopamine receptors. [2]
Asenapine was approved for medical use in the United States in 2009 and Europe in 2010. [6] [2] The first generic versions were approved in 2020. [8] In the United Kingdom it costs the NHS about £100 per month as of 2021. [9] This amount in the United States is about 200 USD. [10]